Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Evaxion A/S changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 10 | 7 | −3 |
| Shares | 884.0K | 439.6K | −444.4K (−50.3%) |
| Value | $5.12M | $3.33M | −$1.79M (−35.0%) |
New holders (2)
Institutions that held Evaxion A/S at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 1,768 | $14.0K | 0.00% |
| Salem Investment Counselors Inc | 5 | $0 | 0.00% |
Sold out (5)
Institutions that held Evaxion A/S at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Luminus Management LLC | 194,929 | $1.15M |
| Alyeska Investment Group, L.P. | 86,726 | $512.0K |
| Altium Capital Management LP | 24,725 | $146.0K |
| Advisor Group Holdings, Inc. | 5,430 | $32.0K |
| Morgan Stanley | 100 | $1.00K |